Phase 3 Trial Methods in the Assessment of Lutetium Lu 177 Dotatate for Advanced Midgut Neuroendocrine Tumors

Video

Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses the methods used during the phase 3 trial to assess lutetium Lu 177 dotatate for midgut neuroendocrine tumors.

Pharmacy Times interviewed Jonathan Strosberg, MD, a professor of medical oncology, section head of the Neuroendocrine Tumor Program, and vice president of Medical Oncology at the Moffitt Cancer Center, on his presentation at the 2021 ASCO Annual Meeting about the NETTER-1 phase 3 trial of lutetium Lu 177 dotatate (Lutathera, Novartis) for midgut neuroendocrine tumors.

During the discussion, Strosberg details the methods used for the phase 3 trial to assess lutetium Lu 177 dotatate as a treatment for patients with advanced midgut neuroendocrine tumors.

Related Videos
3D illustration of heart
Model of a heart
Man experiencing heart pain
3D illustration of heart
Patient with diabetes testing blood sugar levels
Pregnant patient receiving consultation
Physician discussing bone health with a patient
© 2023 MJH Life Sciences

All rights reserved.